

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 10 06 2025**

**FOI Ref No 29153**

**Requested Information:**

A. How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepiti) – any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vyduara) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

B. How many patients have you treated in the last 4 months for acute migraine with:

- Rimegepant (Vyduara)

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

**Response:**

A. How many patients have been treated with the following drugs in the past 4 months:

Royal Cornwall Hospitals Trust have treated the following numbers of patients with the following drugs during Feb 2025 to May 2025. The trust is unable to determine the indication in the time allowable for FOI. Of these patients receiving these drugs, the number who have had a homecare prescription since Feb 2025 with the indication of 'Migraine' (linked to any drug) are shown in brackets after the total:

- Atogepant (Aquipta) – any disease 19 (4)
- Erenumab (Aimovig) - any disease 83 (76)
- Eptinezumab (Vypti) – any disease 0
- Fremanezumab (Ajovy) - any disease 25 (24)
- Galcanezumab (Emgality) - any disease 20 (19)
- Rimegepant (Vydura) – any disease 6 (0)
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – 461 (6)

B. How many patients have you treated in the last 4 months for acute migraine with:

- Rimegepant (Vydura)

Royal Cornwall Hospitals Trust does not record an indication that differentiates acute migraine from other types.

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

No

**Attachment(s):**

**Date Response sent:**



**Royal Cornwall Hospitals**  
NHS Trust